RxDoctor Payments Data

Brittany Smith, PA

Physician Assistant · State College, PANPI 1134679855

Payments from drug & device makers

$2,829in general payments, 2019–2025

Across 120 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$721
  • Lilly USA, LLC$575
  • GSK$397
  • Novo Nordisk$230
  • Pfizer$220
  • Exact Sciences$120
  • plus $567 from 15 others

What the payments were for

  • Food & beverage$2,829100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,829 in reported general payments places this provider in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$27,459
Medicare patients
218
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$43,462
JardianceEmpagliflozin26$30,992
MounjaroTirzepatide16$23,978
OzempicSemaglutide15$19,149
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$12,968
XareltoRivaroxaban14$9,781
Atorvastatin Calcium152$1,770
Albuterol Sulfate HfaAlbuterol Sulfate50$1,432
Levothyroxine Sodium125$1,323
Potassium Chloride36$1,318
Metoprolol Succinate67$1,305
Gabapentin39$1,008
Pantoprazole Sodium44$893
Rosuvastatin Calcium71$782
Amlodipine Besylate93$639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$220$43,46237 claims
Lilly USA, LLCMounjaro$575$23,97816 claims
Novo NordiskOzempic$230$19,14915 claims
GSKTrelegy Ellipta$397$12,96822 claims
Johnson & JohnsonXarelto$29$9,78114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →